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Assessment of Nonischemic Myocardial Fibrosis
Christine Jellis, MD,* Jennifer Martin, MD, PHD,* Jagat Narula, MD, PHD,†
Thomas H. Marwick, MD, PHD*‡
Brisbane, Australia; Orange, California; and Cleveland, Ohio
Myocardial fibrosis is recognized as the pathologic entity of extracellular matrix remodeling. Diffuse, reactive
fibrosis is being increasingly recognized in a variety of conditions despite the absence of ischemia. Regardless of
the etiology, fibrosis leads to increased myocardial stiffness thereby promoting cardiac dysfunction. This may
present clinically with symptoms of cardiac failure although often this is a subclinical disease. Various imaging
modalities and collagen biomarkers have been used as surrogate markers to assess the presence, extent, and
turnover of myocardial fibrosis. Techniques using echocardiography, cardiac magnetic resonance, and nuclear
imaging have been developed to detect early features of systolic and diastolic left ventricular dysfunction and
impaired contractile reserve. Further identification of diffuse reactive fibrosis may be possible with evolving car-
diac magnetic resonance and molecular techniques. The goal of these approaches is to enable targeted therapy
to be instituted earlier, leading to prevention of disease progression and fibrosis accumulation long term.
(J Am Coll Cardiol 2010;56:89–97) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.047t
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tyocardial fibrosis is a pathological entity of extracellular
atrix (ECM) remodeling, often leading to increased myo-
ardial stiffness (1), which may promote abnormalities of
ardiac function (2,3). Fibrosis is most commonly found in
he setting of ischemic scar, but there is increasing recog-
ition of diffuse myocardial fibrosis occurring as a separate
ntity in a variety of conditions in the absence of ischemia,
ncluding hypertensive heart disease and diabetic, hypertro-
hic cardiomyopathy (HCM) and idiopathic dilated cardio-
yopathy (DCM).
athological Fibrosis
CM is synthesized and degraded in a process of continual
issue growth and repair. This structural scaffolding is
onstituted in part from fibrillar collagen, which provides
oth strength and elasticity. Pro-collagen molecules are
ong, stiff, helical structures composed of 3 alpha chains
ach containing approximately 1,000 amino acid residues
4). This ropelike structure is typical for collagens found in
onnective tissue and the myocardium. Types I and III
ollagen predominate in the heart and have exaggerated
ccumulation in the settings of hypertension and diabetes
where type III synthesis is proportionally increased by
yperglycemia) (5,6).
Pro-collagen molecules are synthesized within the endo-
lasmic reticulum of fibroblasts before being secreted into
rom the *University of Queensland, Brisbane, Australia; †University of California-
rvine, Orange, California; and the ‡Cleveland Clinic, Cleveland, Ohio.o
Manuscript received November 13, 2009; revised manuscript received January 19,
010, accepted February 1, 2010.he interstitial space where they undergo cleavage of their
nd-terminal pro-peptide sequences by pro-collagen N- and
-proteinases (PCP) to enable collagen fiber formation (7)
Fig. 1). The activity of the fibrotic process may be charac-
erized because quantification of cleaved pro-peptide corre-
ates with the amount of fibrillar collagen deposited. Activ-
ty of PCP is significantly accelerated by PCP enhancer
roteins (PCPE-1, PCPE-2), which are found in connec-
ive tissue and the myocardium. Up-regulation of myocar-
ial PCPE-1 has been demonstrated by transforming
rowth factor beta and aldosterone in rat models with
own-regulation of PCPE-1 and collagen deposition noted
fter spironolactone therapy (8). Several processes in colla-
en synthesis including inhibition of PCPE or pro-peptide
leavage may provide novel targets for specific cardiac
ntifibrotic therapy.
After cleavage of pro-peptides, resultant collagen mole-
ules are relatively less soluble and initiate self-assembly into
ollagen fibrils that then aggregate to form collagen fibers.
ibrils are strengthened by cross-links formed between
ysine and hydroxylysine residues within and between col-
agen molecules. This is facilitated by deamination of
esidues by lysyl oxidase, yielding aldehyde groups that react
o form covalent bonds (9). Advanced glycation end prod-
cts (AGE), which accumulate with aging and diabetes,
ave been demonstrated to form AGE-mediated cross-links in
ollagen resulting in increased arterial stiffness and resistance to
nzymatic degradation (9). N-epsilon-carboxymethyl-lysine is
major AGE that, with the use of a monoclonal anti-N-
psilon-carboxymethyl-lysine antibody, has been demonstrated
o be significantly higher in the small intramyocardial arteries
f diabetic patients independent of age (10). This microangi-
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derlying fibrosis found in diabetic
cardiomyopathy.
Collagen turnover is regulated
by proteolytic enzymes (matrix
metalloproteinases [MMP] and
tissue inhibitors of metallopro-
teinases [TIMP]) and matricellu-
lar proteins such as secreted pro-
tein, acidic and rich in cysteine
(SPARC). The major MMPs
expressed in the vasculature in-
clude MMP-1, -2, and -9, with
MMP-1 having the highest af-
finity for fibrillar collagen (11).
There are 4 known TIMPs, with
TIMP-1 being the most pre-
dominantly expressed in the
myocardium of heart failure pa-
tients (12). Concentrations of
TIMP-1 are also increased in
diabetes and hypertension, with
associated impaired myocardial
contractility on tissue velocity
parameters, perhaps supporting
its role in pathological fibrosis
13) (Fig. 2). The ratio of circulating MMP/TIMP main-
ains the equilibrium of collagen deposition and degradation
ithin the myocardium (14). Matricellular proteins modu-
ate cell–ECM interactions, with key roles including colla-
Abbreviations
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AGE  advanced glycation
end-products
CMR  cardiac magnetic
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CRIP  Cy5.5-RGD imaging
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Figure 1 Schematic of Collagen Formation
The diagrams illustrate intracellular and extracellular processes involved in pro-col
cleavage of amino- and carboxy-terminal propeptides, and fibrillar collagen fiber foren fibril assembly and post-synthetic pro-collagen process-
ng (15). Increased SPARC expression has been noted in
yocardial fibrosis associated with left ventricular (LV)
ypertrophy and myocardial infarction (MI) (15), although
he exact relationship requires further determination.
Fibrosis can be reparative or reactive. In transmural
yocardial infarction, the protective strength provided by
iscrete macroscopic fibrotic scar prevents myocardial rup-
ure. In contrast, myocardium remote from ischemic scar is
ubject to myocyte hypertrophy and diffuse reactive fibrosis
n a detrimental process of remodeling (16), which appears
ot directly related to ischemia-induced necrosis, but which
eads to increased ventricular stiffness and reduced contrac-
ile reserve. Both types I and III collagen increase at and
emote to the infarct, with synthesis by myofibroblasts in
he infarcted myocardium and fibroblasts in the nonin-
arcted territory and temporal precedence of type III turn-
ver (17). Overall, remote fibrosis is a more significant
eterminant of adverse structural remodeling found in
schemic cardiomyopathy than the infarct scar itself (18).
Reactive fibrosis also occurs in the nonischemic setting.
his diffuse fibrosis is a labile process governed by extrinsic
actors such as blood glucose, blood pressure, and accumu-
ation of AGE. Diabetic cardiomyopathy, characterized by
iffuse myocardial fibrosis and myofibrillar hypertrophy
ithout evidence of valvular, congenital, hypertensive, or
schemic heart disease (19), exemplifies this process. The
emainder of this review will address methods for detection
nd assessment of diffuse, reactive, nonischemic fibrosis.
1. α chains synthesised within the 
endoplasmic reticulum with amino-
(green) and carboxy-terminal (red) 
propeptides in situ
2. Self assembly of three α chains 
into procollagen triple helix
3. Secretion of the procollagen 
molecule into the extracellular 
space where propeptides are 
cleaved by procollagen N- and C-
proteinases to enable collagen 
molecule formation
4. Self-assembly of collagen 
molecules into collagen fibrils 
which are strengthened by cross-
links within and between 
molecules. Fibrils then aggregate 
to form collagen fibers.
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lthough endomyocardial biopsy is the traditional method
or quantification of myocardial interstitial collagen content,
maging techniques and serum collagen biomarkers may be
sed as surrogate markers of myocardial fibrosis (20). These
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Figure 2 Relationship Between Myocardial Contractility
and Proteolytic Enzymes
Inverse correlation between tissue inhibitors of metalloproteinases (TIMP)-1
and early diastolic tissue velocity (e=) in patients with (A) diabetes and (B)
hypertension. Reproduced, with permission, from Tayebjee et al. (13).
Techniques for Noninvasive Assessment of NoniTable 1 Techniques for Noninvasive Assessm
Technique Availability
Echocardiography
Backscatter 
Tissue Doppler imaging 
Nuclear imaging
SPECT–molecular labeling 
PET–perfusable tissue index 
Cardiac magnetic resonance
Delayed enhancement 
T1 mapping 
Tissue tagging 
Collagen biomarkers
PICP 
MMP-1/TIMP-1 
  high;   medium;   low; MMP-1/TIMP-1  ratio of ma
PET  positron emission tomography; PICP  carboxy-terminal pro-peptide
tomography.maging measures may be divided into methods to visualize
brosis (cardiac magnetic resonance imaging [CMR], nu-
lear imaging, and integrated backscatter) and techniques to
ssess subtle subclinical LV systolic and diastolic dysfunc-
ion (predominantly echocardiographic). These tools may
dentify people at risk of cardiac dysfunction from fibrosis,
nabling early deployment of antifibrotic therapy.
Many imaging techniques and modalities have been used
o assess the presence, extent, and turnover of myocardial
brosis. Three steps are important. First, to diagnose
eactive fibrosis, reparative fibrotic scar and inducible isch-
mia secondary to coronary artery disease must be excluded.
econd, some indirect evidence of fibrosis should be
ought—although the noninvasive nature of these tests
ndicates some degree of inference as they have been
alidated against myocardial biopsy studies. Third, the
ssessment may be strengthened by functional evaluation;
yocardial fibrosis results in a spectrum of cardiac dysfunc-
ion, relating to loss of contractile reserve and abnormal
yocardial stiffness, which is proportional to the degree of
CM deposition (Table 1).
issue characterization in nonischemic fibrosis. The re-
ectivity of tissue to ultrasound is a noninvasive measure of
yocardial tissue characterization and collagen deposition
hat has been used for several decades (21). In addition to
he qualitative M-mode and 2-dimensional characteristics
f scar, such as akinesis and increased acoustic brightness,
ackscatter techniques were developed in the 1980s to
uantify myocardial tissue changes characteristic of fibrosis
n conditions such as HCM and hypertension (22). This
uantitative echocardiographic estimation of fibrosis was
redominantly via ultrasonic videodensitometric and texture
nalysis. The correlation between backscatter and histo-
ogically quantitated collagen has been well validated
23). Noninvasively, amplitudes of integrated backscatter
ave also been correlated with elevated pro-collagen con-
entration (24).
mic Fibrosisof Nonischemic Fibrosis
Specificity Quantitative or Functional
 Quantitative
 Functional
 Quantitative
 Quantitative
 Quantitative
 Quantitative
 Functional
 Quantitative
 Quantitative
talloproteinase type 1 to tissue inhibitor of metalloproteinase type 1;scheent
Ease









trix me
of pro-collagen type I; SPECT  single-photon emission computed
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Nonischemic Myocardial Fibrosis July 6, 2010:89–97Two myocardial backscatter parameters have been devel-
ped: 1) magnitude of cyclic variation in integrated back-
catter; and 2) calibrated integrated backscatter. The former
s a marker of regional function, influenced by anisotropy.
lthough it is abnormal in conditions of diffuse fibrosis
25), it has been superseded by the assessment of myocardial
train. Calibrated integrated backscatter is calculated from
issue intensity curves derived offline (Fig. 3); a greater
alibrated integrated backscatter is indicative of greater
brosis. This technique has been used to establish a trans-
ural trend of fibrosis in partial thickness infarction and
ence could potentially be employed to assess fibrotic
radients in conditions, such as diabetic heart disease or
uchenne muscular dystrophy, that have predominantly
ndocardial or epicardial fibrosis, respectively (26,27). Ele-
ated calibrated integrated backscatter also occurs with
ystemic sclerosis, although predominantly in the diffuse
ather than the limited subgroup (28).
Perfusable tissue index is an indirect marker of fibrosis in
oth ischemic and nonischemic cardiomyopathies. This
easurement is obtainable from the difference between
erfusable and nonperfusable tissue on myocardial blood
ow imaging with positron emission tomography (29). In
diopathic dilated cardiomyopathy, regional perfusable tis-
ue index correlates with reduced circumferential shortening
n magnetic resonance tissue tagging, indicating that myo-
ardial fibrosis is related to impairment in contractile func-
Figure 3 Calculation of Calibrated Integrated Backscatter
Measurements of tissue intensity are obtained from sample volumes placed within
parasternal long-axis view. A resultant integrated backscatter curve is derived with
kee, Wisconsin) and enables calibrated integrated backscatter to be calculated by
backscatter intensity of the posterior wall or anteroseptum at end diastole.ion (30). vCM turnover. The measurement of pro-collagen-derived
ro-peptides to detect myocardial fibrosis turnover offers the
ttractiveness of simplicity and a short turnaround time
20). However, concentrations can be affected by comor-
idities including hepatic impairment, metabolic bone dis-
ase, hyperthyroidism, and diabetic nephropathy (31,32).
o date, the carboxy-terminal pro-peptide of pro-collagen
ype I (PICP), amino-terminal pro-peptide of pro-collagen
ype I, and amino-terminal pro-peptide of pro-collagen type
II have been used as markers of collagen turnover in
onditions including: diastolic dysfunction, diabetes, hyper-
ension, and idiopathic dilated cardiomyopathy (20,32–34).
here is a graded association between PICP in peripheral
lood and coronary sinus blood, which is correlated with
yocardial collagen content (35), supporting its use as a
iomarker of collagen type-1 turnover. This association has
ot been validated for other pro-peptides. A strong associ-
tion between collagen volume fraction on endomyocardial
iopsy and serum PICP has previously been identified in
ypertension (31). When used with an echocardiogram,
brosis detection may be further improved as demonstrated
y the association between backscatter and increased PICP
24). Like PICP, the measurable gradient of TIMP-1 and
MP-1 from coronary sinus to peripheral blood supports
heir use as biomarkers (36).
Interstitial alterations including myofibroblastic prolifer-
tion have been demonstrated remote to scar in post-MI
ericardium (yellow), posterior wall (blue), and anteroseptum (green) in a
ard commercial software (Echopac, General Electric Medical Systems, Milwau-
cting mean pericardial integrated backscatter intensity from mean integratedthe p
stand
subtraentricular remodeling (16). Overexpression of myofibro-
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July 6, 2010:89–97 Nonischemic Myocardial Fibrosislastic cell membrane moieties in this setting, such as
ngiotensin receptors and integrins (37), can be exploited
ith specific fluorescent and/or radiotracer labeling to
ocalize myofibroblasts on fluorescence or micro-single-
hoton emission computed tomography imaging. Such
argeted imaging has been performed in the murine
ost-MI model using a fluoresceinated angiotensin peptide
nalog and radiolabeled angiotensin II receptor blocker
technetium-99m losartan) to demonstrate distinct uptake
n the infarct area up to 12 weeks after the event (38). This
argeted myofibroblast receptor imaging was verified on
athologic characterization with localization of tracer to
ollagen-producing myofibroblasts.
Molecular imaging with the RGD peptide (containing
he arginine-glycine-aspartate motif), which binds to inte-
rins such as alphavbeta3, has also been used to evaluate
yocardial remodeling in post-MI murine models. Specif-
cally, Cy5.5-RGD imaging peptide (CRIP) labeled with
echnetium-99m has been developed as a surrogate marker
f thin, newly formed collagen deposition (39). Importantly,
lthough maximum CRIP uptake was observed in the
nfarct area, this had halved by 12 weeks, with the uptake
hen being higher in the peri-infarct zone and remote
yocardium, indicative of newly formed collagen fibers
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Figure 4 Collagen Types in the Infarct and Remote Regions
Temporal characterization of collagen fibers by polarization revealed that the thin o
uration) (A) and increased in the remote area (B) (suggesting ongoing new collage
peptide uptake in both infarct and remote zones (C, D). Adapted, with permissioneflective of myocardial remodeling (Fig. 4). pCRIP imaging has also been employed to demonstrate
he beneficial effect of neurohormonal antagonism on myo-
ardial remodeling post-MI. Captopril, losartan, and spi-
onolactone individually or in combination significantly
educe CRIP uptake in both infarct and remote myocardial
ones correlating with improved LV function on echocar-
iography (40). On histological verification, the extent of
nterstitial fibrosis in the remote myocardium was signifi-
antly decreased whereas collagen maturation in the infarct
one was accelerated, suggesting that neurohormonal antag-
nists can cause prevention of both remote ventricular
emodeling and localized aneurysmal dilation. These mo-
ecular imaging techniques could have clinical applications
n noninvasive estimation of myocardial fibrosis. The mea-
urement of relative uptake with single-photon emission
omputed tomography makes them more likely to find
pplication in the assessment of LV remodeling and pre-
iction of heart failure following MI.
uantification of ECM. CMR imaging has been widely
sed to detect and assess myocardial scar and perfusion and
s the noninvasive gold standard for quantification of focal
yocardial fibrosis. Delayed enhancement CMR highlights
egions of scar or fibrosis, as small as 0.16 g (41), as an area
f high intensity signal (42). Conventionally, this method is
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collagen fibers (green) decreased in the infarct region (suggesting collagen mat-
uction). The prevalence of new collagen fibers paralleled the Cy5.5-RGD imaging
van den Borne et al. (39).B
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Nonischemic Myocardial Fibrosis July 6, 2010:89–970 to 15 min after gadolinium infusion. Retention of
ontrast within the extracellular space results in shortening
f the inversion time (T1) and hyperenhancement relative to
ormal myocardium. Ischemic scar usually results in delayed
nhancement in a subendocardial or transmural distribution
onsistent with the perfusion territories of epicardial coro-
ary arteries, whereas nonischemic fibrosis tends to be
rregular and intramural, even subepicardial, in distribution
43). Fibrosis is frequently identified in LV hypertrophy,
nd delayed enhancement is associated with the degree of
V remodeling (44) and LV end-diastolic pressure, all of
hich further supports the role of interstitial fibrosis in
mpaired relaxation (45).
The main limiting factor with using delayed enhance-
ent CMR in nonischemic cardiomyopathies is that the
brotic process is often diffuse, thereby lacking the normal
onfibrotic myocardium as a frame of reference. Several new
MR techniques have been used in trials for detection of
onischemic myocardial fibrosis. Development of a multi-
lice, single-shot 2-dimensional phase-sensitive inversion
ecovery sequence enables faster detection (24  3 s vs.
85  127 s) and quantification of delayed enhancement
ompared with traditional sequences (46). The use of this
1-insensitive sequence overcomes the reliance on contrast
etween abnormal and normal myocardium. Contrast-
nhanced T1 mapping has also been developed to quantify
iffuse, nonischemic myocardial fibrosis. Using a modified
ook-Locker inversion-recovery prototype sequence (47), a
eries of short-axis images, typically basal, mid-ventricular,
nd apical slices divided into segments, are acquired with
ifferent inversion times. An exponential recovery curve of
ignal intensities at different inversion times is then created
or each designated segment to determine the post-contrast
yocardial T1 time (Fig. 5). The T1 time is then employed
s an index of diffuse fibrosis with a shorter T1 time
orresponding to increased myocardial fibrosis as previously
Figure 5 T1 Mapping for Fibrosis
This post-contrast T1 map of the basal ventricle in short-axis view is demonstrated
nential recovery curve of signal intensities at different inversion times is then prod
basal anterior segment (B).alidated by myocardial biopsy (48) (Fig. 6). By removingeliance on contrasting signal intensity, this method enables
etection of diffuse fibrosis.
T2 relaxation time is another CMR technique employed
o assess tissue properties. In diabetic rats, T2 relaxation
ime was significantly reduced compared with controls and
nversely correlated with collagen fractional area on histol-
gy (49). T2-weighted sequences have also been employed
n the diagnosis of isolated LV noncompaction, where
pical regions of high intensity are reflective of fibrosis (50).
he most sensitive and specific noninvasive method for
uantitation of nonischemic reactive fibrosis needs to be
stablished by comparison of the preceding modalities, in
articular perfusable tissue index, T1 mapping, and PICP,
gainst myocardial biopsy.
region of interest delineating the basal anterior segment (MS06) (A). An expo-
o determine a post-contrast myocardial T1 time of 559.74 ms (red line) for the
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Figure 6 Relationship Between Myocardial Collagen Content
and Post-Contrast T1 Time
Relationship between myocardial collagen content on myocardial biopsy and
post-contrast T1 time on cardiac magnetic resonance imaging. Reproduced,
with permission, from Iles et al. (48).with a
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V ejection fraction, chamber wall thicknesses, and atrial
reas give gross estimates of LV function and filling pres-
ures. Tissue Doppler imaging can be used to assess myo-
ardial tissue velocity and deformation parameters as mea-
ures of myocardial function that may be reduced in the
brotic heart. Reduction of longitudinal function appears to
e the most sensitive marker of subclinical heart disease in
any conditions associated with fibrosis, including diabetes
nd hypertension. This impairment of longitudinal function
eflects the predominant initial involvement of subendocar-
ial fibers, with compensation by mid-wall fibers and
esultant improvement in radial contractility to maintain
verall cardiac function (26).
Peak systolic and early diastolic myocardial tissue veloc-
ties have been used to identify early subclinical disease
espite normal conventional echocardiographic values in
everal progressive, nonischemic fibrotic processes. A reduc-
ion in both parameters has been detected in patients with
iabetes but no evidence of heart failure, and early diastolic
issue velocity has also been found to be reduced with
dvancing age and hypertension; angiotensin-converting
nzyme inhibitor therapy appears to be protective (51,52).
his impairment in myocardial velocity and resultant im-
aired ventricular relaxation may reflect interstitial fibrosis,
ltered cardiomyocyte cytoskeleton properties, or a combi-
ation of both. This relationship is supported by endomyo-
ardial biopsy findings that inversely relate percent fibrosis
o tissue Doppler-derived systolic and early diastolic tissue
elocity (53).
It has recently become possible to assess LV mechanics
ith echocardiographic deformation techniques (strain and
train rate) and magnetic resonance imaging tissue tagging.
train is a fundamental property of matter that relates to the
eformation that occurs after the application of stress (54).
t correlates inversely with the degree of LV dysfunction and
ay become abnormal earlier in cardiomyopathic processes
han other echocardiography techniques. Strain and strain
ate can be measured using tissue Doppler imaging or
-dimensional speckle tracking echocardiography. Both
ethods can detect subclinical heart disease in fibrotic
rocesses, with the predominant planes of strain initially
ffected mirroring the histological location of early fibrosis.
eak systolic longitudinal strain is typically reduced in
iabetes (consistent with initial impairment of endocardial
ontractility), whereas peak systolic radial strain is impaired
n Duchenne muscular dystrophy (an epicardial fibrotic
rocess) (26,55). Impaired deformation parameters have
lso been noted in conditions including: uncontrolled hy-
ertension with elevated serum TIMP-1 levels and systemic
clerosis with cardiac involvement (28,56). Notably, mea-
ures appear to improve in diastolic heart failure after
ldosterone antagonism, perhaps reflective of an antifibrotic
ffect (57). An inverse relationship between deformation
arameters and backscatter in LV hypertrophy and diabetes eurther supports underlying fibrosis as a common pathology
52). In conditions such as severe aortic valve stenosis, Fabry
isease, and HCM, regions of delayed enhancement on
MR also display a characteristic systolic pattern on strain-
ate imaging termed the “double peak sign” (58) (Fig. 7).
Tagging of myocardial tissue with a matrix of radio-
requency saturation enables tissue tracking and calculation
f rotation and displacement in 3 dimensions (59). This
MR technique has been used to assess cardiac motion and
eformation in conditions such as HCM, where reduced
egional myocardial shortening with increased LV torsion is
oted (60). The combination of tissue tagging with delayed
Figure 7 SR Imaging Displaying the “Double Peak Sign”
Longitudinal strain rate curve from a segment with delayed enhancement on
cardiac magnetic resonance imaging displaying the “double peak sign” indica-
tive of fibrosis. Reproduced, with permission, from Weidemann et al. (58).
AVC  aortic valve closure; CMR  cardiac magnetic resonance imaging;
SR  strain rate.nhancement CMR may enable stratification of occult
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rophies (61).
onclusions
onischemic fibrosis is being increasingly recognized in
ultiple etiologies as a pathological entity. Often this
anifests as diastolic dysfunction or heart failure with
reserved ejection fraction, both of which have important
rognostic implications. The ability to simply, rapidly, and
ccurately identify and quantify the contribution of fibrosis
o these disease processes with imaging techniques and
iomarkers may allow a more specific and timely strategy to
e applied in the treatment of these conditions.
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